Israeli Colonoscopy Tech Gets Approval From Top Medical Journal

Israeli AI-assisted colonoscopy technology has been given the seal of approval from the internationally respected Lancet Digital Health journal, following an extensive study of its capabilities.

The novel polyp detection system developed by Haifa-based MAGENTIQ-EYE was studied by the Lancet over a 14-month period at 10 leading medical centers around the world, involving 31 endoscopists and 952 patients.

The study, titled “A computer-aided polyp detection system in screening and surveillance colonoscopy: an international, multicentre, randomised, tandem trial,” found that the MAGNETIQ-EYE platform increases the average detection rate for adenoma (non-cancerous or pre-cancerous tumors) by 7 percent, and had a 17-percent lower rate of missed detection of adenoma.

“We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research,” said Dror Zur, founder and CEO of MAGENTIQ EYE.

“It is important to note that measuring changes in both ADR [adenoma detection rate] and AMR [adenoma miss rate] in a single study is a novelty. In addition to FDA approval that we received last year, this milestone is a testament to the impact of MAGENTIQ-COLO in advancing the quality of colonoscopy and setting new healthcare standards in order to save more and more lives.”

The MAGENTIQ-COLO platform is in use in the United States and in Europe.